Skip to main content

Advertisement

Log in

Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas

  • Published:
Journal of Biomedical Science

Summary

Cancer has been the leading cause of death in Taiwan over the past two decades and liver cancer is the leading cause of all cancer deaths in Taiwan with a trend of increase in incidence. Therapeutic options and efficacy for liver cancer have been limited and the 5-year survival rate is less than 7% in the Unite States. The study was conducted to establish a histoculture system of human hepatocellular carcinomas (HCC) for biological and pharmacological studies and to determine the efficacy of anticancer drugs with the established HCC histocultures. Patient HCC tissues freshly obtained after surgeries were prepared and histocultured. The histocultured HCC were treated with doxorubicin and paclitaxel of various concentrations for 96-h. Upon drug treatments, the activity of tumor cell proliferation and extent of cell death induction were measured and changes of the α-fetoprotein levels in the culture medium were determined. We demonstrated that human HCC can be successfully cultured in a 3-dimensional histoculture system and used for pharmacological studies. Doxorubicin and paclitaxel showed concentration-dependent activities in anti-proliferation and cell death induction against the human HCC. Inhibitory effects of both drugs on α-fetoprotein production of the cultured HCC were in agreement with their anti-proliferative effects. Exposure time-dependent antitumoral effects of paclitaxel treatments at 3-, 24-, and 96-h against the histocultured HCC PLC/PRF/5 xenograft tumors were also observed. In conclusion, we have demonstrated a histoculture system for patient HCC and it can be utilized in selection of active drugs prior to treatments in patients and in evaluation of new agents against HCC, for which therapeutic agents are in desperate needs worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montalto G., Cervello M., Giannitrapani L., Dantona F., Terranova A., Castagnetta L.A.,Epidemiology, risk factors, natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 963:13–20 (2002)

    Article  PubMed  Google Scholar 

  2. El-Serag H.B.,Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 35(5 Suppl 2):S72–78 (2002)

    Article  PubMed  Google Scholar 

  3. Llovet J.M., Burroughs A., Bruix J., Hepatocellular carcinoma. Lancet 362:1907–1917 (2003)

    Article  PubMed  Google Scholar 

  4. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5-S16. (2004)

    Article  PubMed  Google Scholar 

  5. Lee Y.T., Primary carcinoma of the liver: diagnosis, prognosis, and management. J. Surg. Oncol. 22:17–25 (1983)

    Article  PubMed  CAS  Google Scholar 

  6. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J., Cancer statistics, 2006. CA. Cancer J. Clin. 56:106–130 (2006)

    Article  PubMed  Google Scholar 

  7. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336:1855–1859 (1997)

    Article  PubMed  CAS  Google Scholar 

  8. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J.; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease N. Engl. J. Med. 351:1521–1531 (2004)

    Article  PubMed  CAS  Google Scholar 

  9. Lee C.L., Ko Y.C., Choong C.S., Survival rate for liver cancer in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 63:16–20 (2000)

    CAS  Google Scholar 

  10. Mor E., Kaspa R.T., Sheiner P., Schwartz M., Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann. Intern. Med. 129: 643–653 (1998)

    PubMed  CAS  Google Scholar 

  11. Nagorney D.M., van Heerden J.A., Ilstrup D.M., Adson M.A.. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106:740–749, (1989)

    PubMed  CAS  Google Scholar 

  12. Tsuzuki T., Sugioka A., Ueda M., Iida S., Kanai T., Yoshii H., Nakayasu K., Hepatic resection for hepatocellular carcinoma. Surgery 107:511–520, (1990)

    PubMed  CAS  Google Scholar 

  13. Whang-Peng J., Chao Y., Clinical trials of HCC in Taiwan. Hepatogastroenterology 45:1937–1943, (1998)

    PubMed  CAS  Google Scholar 

  14. Furukawa T., Kubota T., Hoffman RM, Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1:305–311 (1995)

    PubMed  CAS  Google Scholar 

  15. Robbins K.T., Connors K.M., Storniolo AM., Hanchett C, Hoffman R.M., Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch. Otolaryngol. Head Neck Surg. 120:288–292 (1994)

    PubMed  CAS  Google Scholar 

  16. Tanino H., Oura S., Hoffman R.M., Kubota T., Furukawa T., Arimoto J., Yoshimasu T., Hirai I., Bessho T., Suzuma T., Sakurai T., Naito Y., Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res. 21:4083–4086 (2001)

    PubMed  CAS  Google Scholar 

  17. Chen C.T., Gan Y., Au J.L., Wientjes M.G., Androgen-dependent and – independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res. 58: 2777–2783, (1998)

    PubMed  CAS  Google Scholar 

  18. Gan Y., Wientjes M.G., Badalament R.A., Au J.L., Pharmacodynamics of doxorubicin in human bladder tumors. Clin. Cancer Res. 2:1275–1283 (1996)

    PubMed  CAS  Google Scholar 

  19. Tangkijvanich P., Anukulkarnkusol N., Suwangool P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., Poovorawan Y., (2000) Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 31:302–308

    Article  PubMed  CAS  Google Scholar 

  20. Soresi M., Magliarisi C., Campagna P., Leto G., Bonfissuto G., Riili A., Carroccio A, Sesti R, Tripi S, Montalto G (2003) Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 23:1747–1753

    PubMed  CAS  Google Scholar 

  21. Ohie S., Udagawa Y., Kozu A., Komuro Y., Aoki D., Nozawa S., Moossa A.R., Hoffman R.M. (2000) Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res. 20:2049–2054

    PubMed  CAS  Google Scholar 

  22. Hoffman R.M., (2000) The clinical benefit of the histoculture drug response assay. Jpn. J. Cancer Chemotherapy 27(Suppl 2):321–322

    Google Scholar 

  23. Hoffman R.M., (1991) Three-dimensional histoculture: origins and applications in cancer research. Cancer Cell 3:86–92

    CAS  Google Scholar 

  24. Boess F., Kamber M., Romer S., Gasser R., Muller D., Albertini S., Suter L. (2003) Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73:386–402

    Article  PubMed  CAS  Google Scholar 

  25. Jaeschke H.. (2003) Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? Hepatology 38:1053–1055

    Article  PubMed  CAS  Google Scholar 

  26. Ariyoshi Y., Shimahara M., Tanigawa N.. (2003) Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol. 39:701–707

    Article  PubMed  CAS  Google Scholar 

  27. Hirano Y., Kageyama S., Ushiyama T., Suzuki K., Fujita K.. (2001) Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res. 21:4061–4066

    PubMed  CAS  Google Scholar 

  28. Speth P.A., Linssen P.C., Holdrinet R.S., Haanen C.. 1987 Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin. Pharmacol. Ther. 41:661–665

    Article  PubMed  CAS  Google Scholar 

  29. Bugat R., Robert J., Herrera A., Pinel M.C., Huet S., Chevreau C., Boussin G., Roquain J., Carton M.. (1989) Clinical pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. Eur. J. Cancer Clin. Oncol. 25:505–511

    Article  PubMed  CAS  Google Scholar 

  30. Adams D.J., In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a novel DNA intercalator. Cancer Res. 49:6615–6620 (1989)

    PubMed  CAS  Google Scholar 

  31. Olweny C.L., Toya T., Katongole-Mbidde E., Mugerwa J., Kyalwazi S.K., Cohen H., Treatment of hepatocellular carcinoma with adriamycin. Cancer 36:1250–1257 (1975)

    Article  PubMed  CAS  Google Scholar 

  32. Doci R., Bignami P., Bozzetti F., Bonfanti G., Audisio R., Colombo M., Gennari L., Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61:1983–1987 (1988)

    Article  PubMed  CAS  Google Scholar 

  33. Barone M., Ettorre G.C., Ladisa R., Schiavariello M., Santoro C., Francioso G., Vinciguerra V., Francavilla A., Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 50:183–187 (2003)

    PubMed  Google Scholar 

  34. Raoul J.L., Heresbach D., Bretagne J.F., Bentue Ferrer D., Duvauferrier R., Bourguet P., Messner M. and Gosselin M., Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70: 585–590, 1992

    Google Scholar 

  35. Lai C.L., Wu P.C., Chan G.C., Lok A.S., Lin H.J., Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483 (1988)

    Article  PubMed  CAS  Google Scholar 

  36. Cheng J.C., Chuang V.P., Cheng S.H., Huang A.T., Lin Y.M., Cheng T.I., Yang P.S., You D.L., Jian J.J., Tsai S.Y., Sung J.L., Horng C.F., Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 47:435–442 (2000)

    Article  PubMed  CAS  Google Scholar 

  37. Wilson W.H., Berg S.L., Bryant G., Wittes R.E., Bates S., Fojo A., Steinberg S.M., Goldspiel B.R., Herdt J., O’Shaughnessy J., et al Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 12:1621–1629 (1994)

    PubMed  CAS  Google Scholar 

  38. Gligorov J, Lotz JP.. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2):3–8 (2004)

    Article  PubMed  CAS  Google Scholar 

  39. Strumberg D., Erhard J., Harstrick A., Klaassen U., Muller C., Eberhardt W., Wilke H., Seeber S., Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 34:1290–1292 (1998)

    Article  PubMed  CAS  Google Scholar 

  40. Panday V.R.N., ten Bokkel Huinink W.W., Vermorken J.B., Rosing H., Koopman F.J., Swart M., Schellens J.H., Beijnen J.H., Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol. Res. 40:67–74 (2004)

    Article  Google Scholar 

  41. Seidman A.D., Hochhauser D., Gollub M., Edelman B., Yao T.J., Hudis C.A., Francis P., Fennelly D., Gilewski T.A., Moynahan M.E., Currie V., Baselga J., Tong W., O’Donaghue M., Salvaggio R., Auguste L., Spriggs D., Norton L., Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 14:1877–1884 (1996)

    PubMed  CAS  Google Scholar 

  42. Minemura M., Tanimura H., Tabor E., Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 15:559–563 (1999)

    PubMed  CAS  Google Scholar 

  43. Nies A.T., Konig J., Pfannschmidt M., Klar E., Hofmann W.J., Keppler D., Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94:492–499 (2001)

    Article  PubMed  CAS  Google Scholar 

  44. Chao Y., Chan W.K., Birkhofer M.J., Hu O.Y, Wang S.S., Huang Y.S., Liu M, Whang-Peng J., Chi K.H., Lui W.Y., Lee S.D.. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer 78:34–39 (1998)

    PubMed  CAS  Google Scholar 

  45. Fuchs J., Habild G., Leuschner I., Schweinitz D.V., Haindl J., Knon E., Paclitaxel: an effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma. Med. Pediatr. Oncol. 32:209–215 (1999)

    Article  PubMed  CAS  Google Scholar 

  46. Chang A.Y., Boros L., Garrow G., Asbury R.. (1995) Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin. Oncol. 22(3 Suppl 6):124–127 (1995)

    PubMed  CAS  Google Scholar 

  47. Younes A., Ayoub J.P., Hagemeister F.B., McLaughlin P., Sarris A., Rodriguez M.A., Swan F. Jr., Romaguera J.E., Martin J., Cabanillas F., No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin’s lymphoma refractory to a 3-hour infusion schedule. J. Clin. Oncol. 14:543–548 (1996)

    PubMed  CAS  Google Scholar 

  48. Markman M., Rose P.G., Jones E., Horowitz I.R., Kennedy A., Webster K., Belinson J., Fusco N., Fluellen L., Kulp B., Peterson G., McGuire W.P., Ninety-six hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J. Clin. Oncol. 16:1849–1851 (1998)

    PubMed  CAS  Google Scholar 

  49. Lopez R.R. Jr., Pan S.H., Lois J.F., McMonigle M.E., Hoffman A.L., Sher L.S., Lugo D., Makowka L.,.Transarterial chemoembolization is a safe treatment for unresectable hepatic malignancies. Ann. Surg. 63:923–926 (1997)

    Google Scholar 

  50. Yoon C.J., Chung J.W., Park J.H., Yoon Y.H., Lee J.W., Jeong S.Y., Chung H.,. Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229:126–131 (2003)

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants BP-091-CF03, BP-092-PP-10, and BP-093-PP-11 of The National Health Research Institutes and NSC 92-2218-E-400-001 from National Science Council, Taiwan, R.O.C. We would like to thank Dr. Y. S. Chao, Dr. C. M. Chang, Ms. H. W. Chu and Ashley Chen for their administrative supports and Mung-Pei Tsai for technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chiung-Tong Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chuu, JJ., Liu, J.M., Tsou, MH. et al. Effects of paclitaxel and doxorubicin in histocultures of hepatocelular carcinomas. J Biomed Sci 14, 233–244 (2007). https://doi.org/10.1007/s11373-006-9141-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11373-006-9141-3

Keywords

Navigation